Accueil・Liste d'Actions・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Fermé

SecteurSoins de santé

280.45 0.11

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

278.27

Max

286.83

Chiffres clés
By Trading Economics
Revenu	62M 49M
Ventes	12M 64M
P/E Moyenne du Secteur	29.524 57.366
BPA	2.22
Marge bénéficiaire	76.159
Employés	47
EBITDA	87M 72M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+25.23% upside

Dividendes
By Acuity
Prochains Résultats	5 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-267M 5.6B
Ouverture précédente	280.34
Clôture précédente	280.45

Sentiment de l'Actualité

By Acuity

35%

65%

136 / 340 Classement par Healthcare

Ligand Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 19:46 UTC

Ligand Pharmaceuticals Inc is trading higher, benefiting from a favorable market environment amid declining crude oil prices and lower Treasury yields.

24 août 2026, 19:56 UTC

Ligand Pharmaceuticals is trading lower during Monday's session, marking the fourth consecutive day of declines. No specific news has been identified to explain the drop.

21 août 2026, 19:36 UTC

News

Ligand Pharmaceuticals is gaining today, supported by strong long-term performance and a market capitalization of $5.76 billion.

19 août 2026, 19:11 UTC

Ligand Pharmaceuticals Inc is rising today, driven by strong momentum in the Pharmaceuticals sub-sector and unusually high market volume.

18 août 2026, 19:16 UTC

Ligand Pharmaceuticals Inc is trading lower, continuing a downward trend amid rising U.S. Treasury yields and inflation concerns related to geopolitical tensions.

17 août 2026, 20:06 UTC

Ligand Pharmaceuticals Inc is declining during Monday's session, amid broader economic concerns following a drop in U.S. retail sales for July.

14 août 2026, 19:46 UTC

News

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

13 août 2026, 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12 août 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11 août 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10 août 2026, 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7 août 2026, 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6 août 2026, 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5 août 2026, 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3 août 2026, 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31 juil. 2026, 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30 juil. 2026, 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29 juil. 2026, 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28 juil. 2026, 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27 juil. 2026, 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24 juil. 2026, 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23 juil. 2026, 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21 juil. 2026, 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Comparaison

Variation de prix

Ligand Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

25.23% hausse

Prévisions sur 12 Mois

Moyen 350.86 USD 25.23%

Haut 390 USD

Bas 326 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

136 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.